1. Home
  2. STEP vs ABCL Comparison

STEP vs ABCL Comparison

Compare STEP & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEP

StepStone Group Inc.

N/A

Current Price

$44.26

Market Cap

3.9B

Sector

Finance

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

N/A

Current Price

$12.53

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STEP
ABCL
Founded
2007
2012
Country
United States
Canada
Employees
N/A
562
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
STEP
ABCL
Price
$44.26
$12.53
Analyst Decision
Buy
Strong Buy
Analyst Count
10
11
Target Price
★ $67.60
$16.70
AVG Volume (30 Days)
947.6K
★ 5.0M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 4.26%
N/A
EPS Growth
N/A
★ 10.91
EPS
N/A
★ N/A
Revenue
★ $1,993,603,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$17.50
$7.91
P/E Ratio
N/A
★ N/A
Revenue Growth
69.69
★ 160.56
52 Week Low
$38.85
$2.75
52 Week High
$77.80
$14.98

Technical Indicators

Market Signals
Indicator
STEP
ABCL
Relative Strength Index (RSI) 42.82 51.00
Support Level $40.83 $11.78
Resistance Level $46.56 $12.88
Average True Range (ATR) 1.56 0.82
MACD -0.02 -0.24
Stochastic Oscillator 28.20 24.06

Price Performance

Historical Comparison
STEP
ABCL

About STEP StepStone Group Inc.

StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: